Login
$CGEM
$14.84 +$0.30 (2.06%) Close

Company Executives

$CGEM Management Team

Mr. Anthony Rosenberg

Independent Chairman of the Board

Age 71
Compensation $258.4K USD
Sex Male

Mr. Nadim Ahmed

President

Chief Executive Officer

Director

Age 57
Compensation $7.684M USD
Sex Male

Ms. Mary Fenton

Chief Financial Officer

Principal Financial Officer

Principal Accounting Officer

Age 61
Compensation $4.142M USD
Sex Female

Ms. Jacquelyn Sumer

Chief Legal and Compliance Officer

Company Secretary

Age 47
Compensation -
Sex Female

Dr. Jennifer Michaelson

Chief Scientific Officer

Age 58
Compensation -
Sex Female

Dr. Jeffrey Jones

Chief Medical Officer

Age 54
Compensation $3.388M USD
Sex Male

Ms. Corinne Savill

Chief Business Officer

Age 65
Compensation $486.2K USD
Sex Female
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
3.7 years
from year joined
CEO also chairs the board
No
Anthony Rosenberg
Director Age On board Independent Committees Other public boards 2025 pay Source
Nadim Ahmed
58 2021
5 years
Not independent None stated Disc Medicine, Inc. Paid as CEO
Stephen Webster
65 2020
6 years
Independent
Audit Committee · Chair Compensation Committee
NextCure, Inc. $283,186
Mittie Doyle, M.D., FACR
61 2025
1 year
Independent
Nominating and Corporate Governance Committee
None stated $376,928
David Meek
62 2024
2 years
Independent
Audit Committee
Swedish Orphan Biovitrum AB, uniQure N.V. $268,639
Andrew Allen, M.D., Ph.D.
59 2025
1 year
Independent
Compensation Committee
None stated $377,326
Anthony Rosenberg
72 2017
9 years
Independent
Audit Committee
argenx SE, Oculis Holding AG $306,329
Mary Thistle
66 2024
2 years
Independent
Nominating and Corporate Governance Committee
Q32 Bio Inc., Entrada Therapeutics, Inc., Aktis Oncology, Inc. $49,781

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support